The following is a summary of the Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript:
Financial Performance:
Kamada Ltd. reported a Q2 2024 revenue of $42.5 million, a 13% increase from Q2 2023.
Adjusted EBITDA for Q2 2024 was $9.1 million, a 51% increase compared to Q2 2023.
First half 2024 revenues reached $80.2 million, an 18% increase year-over-year, and adjusted EBITDA was $16.6 million, a 68% increase.Gross profit for Q2 2024 was $19 million with a margin of 45%, compared to $14.4 million or 39% margin year-over-year.
Net income for Q2 2024 was $4.4 million, compared to $1.8 million in Q2 2023.
Business Progress:
Launched first biosimilar product in Israel, planning another by year-end.
Expanding U.S. plasma collection operations with new centers in Beaumont, Houston, and San Antonio.
Ongoing pivotal Phase 3 clinical trial of inhaled AAT product.
Opportunities:
Anticipate increasing importance of biosimilars in distribution with potential annual sales between $30 million to $34 million.
Each new plasma collection center contributes $8 million to $10 million annual revenue.
Aiming for double-digit growth beyond 2024 supported by business development and M&A opportunities.
Risks:
Biosimilar product launches and clinical trials involve inherent risks, including regulatory and market acceptance challenges.
Plasma collection expansion and successful execution of M&A transactions are critical for sustained growth.
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
